Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
One purpose of this study is to find out if a new combination of immune system treatments
(MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection
("immunity") against the myeloma cells. A second purpose is to find out how well this
combination of immune system treatments is able to control the myeloma.